Aide to RFK Jr. says White House is pushing for global price parity on GLP-1 drugs for weight loss. Read more here.

Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...

Shares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license ...

While the early week buzz centered around the U.S.-China trade agreement, another critical development unfolded quietly but ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...

In this article, we will take a look at the 12 Major Stocks to Buy According to Billionaires. The U.S. stock market had one of the worst starts, at least the worst start to a presidency since 1928.

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral ...

Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and ...

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...

Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.